Resources from the same session
5MO - First-line adagrasib (ADA) with pembrolizumab (PEMBRO) in patients (pts) with advanced/metastatic KRASG12C-mutated non-small cell lung cancer (NSCLC) and PD-L1 =50% from the phase II portion of KRYSTAL-7
Presenter: Marina Garassino
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
6MO - Safety and clinical activity of daraxonrasib (RMC-6236) in RAS mutant non-small cell lung cancer (NSCLC)
Presenter: Salman Punekar
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
LBA1 - First-line (1L) fulzerasib + cetuximab in KRAS G12Cm advanced NSCLC: Updated efficacy and safety from KROCUS study
Presenter: Margarita Majem Tarruella
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
Invited Discussant 5MO, 6MO and LBA1
Presenter: Adrianus Johannes De Langen
Session: Mini Oral session 1
Resources:
Slides
Webcast
7MO - A phase II trial of tobemstomig (tobe) + platinum-based chemotherapy (chemo) vs pembrolizumab (pembro) + chemo in patients (pts) with untreated locally advanced or metastatic non-small cell lung cancer (NSCLC)
Presenter: Ernest Nadal
Session: Mini Oral session 1
Resources:
Abstract
8MO - Subcutaneous (SC) versus intravenous (IV) pembrolizumab (Pembro) plus chemotherapy (CT) in metastatic non-small cell lung cancer (mNSCLC): Phase III MK-3475A-D77 trial
Presenter: Enriqueta Felip
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
Invited Discussant 7MO and 8MO
Presenter: Rosalyn Juergens
Session: Mini Oral session 1
Resources:
Slides
Webcast
LBA2 - Taletrectinib vs crizotinib in ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC): A matching-adjusted indirect comparison (MAIC)
Presenter: Misako Nagasaka
Session: Mini Oral session 1
Resources:
Abstract
9MO - Amivantamab, lazertinib and bevacizumab in EGFR-mutant advanced NSCLC with acquired resistance to 3rd generation EGFR-TKI: Final results from the phase II ETOP AMAZE-lung trial
Presenter: Ross Soo
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
10MO - Preventing moderate to severe dermatologic adverse events in first-line EGFR-mutant advanced NSCLC treated with amivantamab plus lazertinib: Early success of the COCOON trial
Presenter: Nicolas Girard
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast